The Case for Treating Cholesterol Before Plaque Appears | Dr Thomas Dayspring and Dr Dan Soffer

What It Covers

Lipidologists Thomas Dayspring and Dan Soffer examine primary prevention of atherosclerosis, covering how ApoB-containing lipoproteins drive plaque formation, when to initiate lipid-lowering therapy before a cardiovascular event occurs, how the 2026 dyslipidemia guidelines expand risk assessment to age 30, and which pharmacologic options—statins, ezetimibe, and PCSK9 inhibitors—best reduce long-term cardiovascular risk.

Key Questions Answered

• •ApoB as the necessary substrate: Atherosclerosis cannot form without ApoB-containing lipoproteins penetrating the arterial wall and depositing cholesterol. No ApoB means no plaque, regardless of how many other risk factors are present—smoking, hypertension, or diabetes cannot cause atherosclerosis independently. This makes ApoB the single non-negotiable target in cardiovascular risk management, and measuring it at every lipid panel provides more actionable data than LDL cholesterol alone.
• •LDL-years threshold for plaque risk: Multiply a patient's age by their LDL cholesterol in mg/dL. When that product exceeds 5,000, clinically significant plaque burden and event risk become likely. A 12-year-old with an LDL of 230 mg/dL already crosses this threshold. This framework helps clinicians justify early pharmacologic intervention in younger patients who appear low-risk by conventional ten-year risk calculators but carry substantial cumulative exposure.
• •2026 guideline risk calculator expansion: The new Prevent ASCVD risk calculator extends assessment from ages 40–75 down to ages 30–79, includes a 30-year risk projection, incorporates kidney function, and adds ZIP code as a proxy for socioeconomic deprivation. This allows clinicians to identify and counsel patients in their thirties who carry elevated long-term risk but score low on ten-year calculations, enabling earlier conversations about lifestyle and pharmacologic intervention.
• •Universal lipid screening schedule: Screen all children between ages 9 and 11 to detect familial hypercholesterolemia, which affects roughly 1 in 300 people. Rescreen at ages 17–21, then every five years through the thirties. Screen at age two if either parent has confirmed or suspected familial hypercholesterolemia. Homozygous FH in its most severe form can cause fatal heart attacks before age 15, making early identification and immediate treatment critical for affected children.
• •Treat before plaque appears with strong family history: A male in his early thirties with an ApoB of 90–120 mg/dL and a first-degree relative with premature cardiovascular disease warrants lipid-lowering therapy even with a negative coronary CT angiogram. Dayspring recommends low-dose statin or ezetimibe in this scenario, targeting ApoB reduction to approximately 60–70 mg/dL, citing the lower-for-longer principle and the absence of meaningful safety concerns with currently available agents.
• •PCSK9 inhibitors and ezetimibe lead on tolerability: Among available lipid-lowering drug classes, PCSK9 inhibitors and ezetimibe carry the fewest tolerability complaints. Statins, despite 30-plus major cardiovascular outcome trials supporting their use, generate the most patient-reported side effects, particularly muscle symptoms. Bempedoic acid avoids muscle issues by acting only in the liver via a liver-specific enzyme conversion, but its roughly 20% LDL reduction makes it a fourth-line option behind statins, ezetimibe, and PCSK9 inhibitors for most patients.
• •Age-adjusted cardiovascular mortality has fallen over 80%: From 1970 to the present, age-adjusted cardiovascular mortality in the United States has declined by more than 80%, driven by advances in emergency care, revascularization, and pharmacologic therapy. Despite this progress, residual risk remains substantial, particularly among undertreated primary prevention patients. The opportunity to further reduce this burden lies in earlier risk identification, routine ApoB and Lp(a) measurement, and initiating therapy in younger adults before plaque becomes detectable on imaging.